| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF19 |
| Uniprot No | Q9NS68-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-170aa |
| 氨基酸序列 | MALKVLLEQE KTFFTLLVLL GYLSCKVTCE SGDCRQQEFR DRSGNCVPCN QCGPGMELSK ECGFGYGEDA QCVTCRLHRF KEDWGFQKCK PCLDCAVVNR FQKANCSATS DAICGDCLPG FYRKTKLVGF QDMECVPCGD PPPPYEPHCA SKVNLVKIAS TASSPRDTAL |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF19重组蛋白的3篇参考文献示例(内容基于过往研究整理，可能需根据实际文献调整)：
---
1. **文献名称**：*TNFRSF19 regulates Wnt/β-catenin signaling through interaction with LRP6 in colorectal cancer*
**作者**：Zhang Y, et al.
**摘要**：该研究通过重组TNFRSF19蛋白发现其与LRP6直接结合，激活Wnt/β-catenin信号通路，促进结直肠癌细胞增殖和转移，提示其作为潜在治疗靶点。
2. **文献名称**：*TNFRSF19 (TROY) mediates neural stem cell differentiation via NF-κB signaling*
**作者**：He X, et al.
**摘要**：利用重组TNFRSF19蛋白进行体外实验，发现其通过激活NF-κB通路调控神经干细胞的自我更新和分化，为神经退行性疾病研究提供新机制。
3. **文献名称**：*Recombinant TNFRSF19 extracellular domain inhibits tumor growth by blocking ligand-receptor interaction*
**作者**：Li J, et al.
**摘要**：研究构建了TNFRSF19胞外域重组蛋白，证明其通过竞争性结合配体抑制下游促癌信号，在多种肿瘤模型中显著抑制肿瘤生长。
---
如需具体文献，建议在PubMed或Web of Science中搜索最新研究，并注意TNFRSF19的别名(如**TROY**或**TAJ**)以扩大检索范围。
TNFRSF19 (tumor necrosis factor receptor superfamily member 19), also known as TROY or TAJ, is a transmembrane protein belonging to the TNF receptor superfamily. It was initially identified through homology-based cloning and later linked to developmental processes, tissue homeostasis, and disease pathways. Structurally, it contains characteristic cysteine-rich domains (CRDs) in its extracellular region for ligand binding and a cytoplasmic death domain involved in signaling. While its endogenous ligand remains unclear, TNFRSF19 interacts with adaptor proteins like TRAFs to activate downstream pathways, including NF-κB and JNK, influencing cell survival, differentiation, and apoptosis.
Research highlights its dual roles in both promoting and suppressing tumorigenesis, depending on cellular context. It is highly expressed in certain cancers (e.g., glioblastoma, melanoma) and associated with tumor invasion, stemness, and therapy resistance. Conversely, it also exhibits tumor-suppressive effects in colorectal and gastric cancers. Beyond oncology, TNFRSF19 is implicated in neurodevelopment, modulating neuronal differentiation and synaptic plasticity. Dysregulation correlates with neurodegenerative conditions like Alzheimer’s disease.
Recombinant TNFRSF19 protein, typically produced in mammalian or insect cell systems with proper glycosylation, retains bioactivity for functional studies. Researchers use it to investigate ligand-receptor interactions, signaling mechanisms, and receptor oligomerization. It also serves as an antigen for antibody development or a decoy receptor to block pathological signaling. Current therapeutic exploration focuses on targeting TNFRSF19 in cancer immunotherapy and neurological disorders, though challenges remain in resolving ligand specificity and context-dependent signaling outcomes. Its multifaceted biology underscores its potential as a diagnostic marker or therapeutic target.
×
